Brentuximab Vedotin
drugOn this page
Also known as AdcetrisBrentuximab vedotin brentuximabBrentuximab vedotinaBrentuximab vedotineCAC-10CAC10Monoclonal antibody sgn-30Sgn 30SGN-35
Summary
Brentuximab Vedotin (CHEMBL1742994) is an approved antibody drug conjugate (ATC L01FX05) targeting TNFRSF8; indicated across 28 conditions including hodgkins lymphoma and non-hodgkin lymphoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody drug conjugate
- ATC class: L01FX05
- Targets: 1 (TNFRSF8)
- Indications: 28 conditions
- Clinical trials: 165
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1742994 |
| Name | Brentuximab Vedotin |
| Type | Antibody drug conjugate |
| Max phase | 4 |
| ATC | L01FX05 |
Also known as: Adcetris, Brentuximab vedotin, Brentuximab vedotin brentuximab, Brentuximab vedotina, Brentuximab vedotine, CAC-10, CAC10, Monoclonal antibody sgn-30, Sgn 30, SGN-35, BRENTUXIMAB VEDOTIN
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| TNFRSF8 | CD30 | Inhibition | 5.5% | P28908 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): TNFRSF8.
Top Reactome pathways
1 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| TNFs bind their physiological receptors | 1 | TNFRSF8 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 1 |
| negative regulation of cell population proliferation | 1 |
| positive regulation of TRAIL production | 1 |
| positive regulation of tumor necrosis factor production | 1 |
| positive regulation of apoptotic process | 1 |
| cellular response to mechanical stimulus | 1 |
Indications & clinical
Indications
28 indications (5 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Hodgkins lymphoma | 4 | MONDO:0004952 | EFO:0000183 |
| non-Hodgkin lymphoma | 4 | MONDO:0018908 | EFO:0005952 |
| neoplasm | 4 | MONDO:0005070 | EFO:0000616 |
| anaplastic large cell lymphoma | 4 | MONDO:0020325 | EFO:0003032 |
| lymphoma | 3 | MONDO:0005062 | EFO:0000574 |
| mycosis fungoides | 3 | MONDO:0009691 | EFO:1001051 |
| diffuse large B-cell lymphoma | 3 | MONDO:0018905 | EFO:0000403 |
| primary cutaneous T-cell non-Hodgkin lymphoma | 3 | MONDO:0000607 | EFO:0002913 |
| germ cell tumor | 2 | MONDO:0005040 | EFO:0000514 |
| diffuse scleroderma | 2 | MONDO:0005019 | EFO:0000404 |
| Sezary syndrome | 2 | MONDO:0017844 | EFO:1000785 |
| peripheral T-cell lymphoma, not otherwise specified | 2 | MONDO:0004964 | EFO:0000211 |
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| neoplasm of mature B-cells | 2 | MONDO:0004949 | EFO:0000096 |
| mast cell leukemia | 2 | MONDO:0020334 | EFO:0007359 |
| graft versus host disease | 2 | MONDO:0013730 | MONDO:0013730 |
| enteropathy-associated T-cell lymphoma | 2 | MONDO:0019473 | MONDO:0019473 |
| follicular lymphoma | 2 | MONDO:0018906 | MONDO:0018906 |
| systemic lupus erythematosus | 2 | MONDO:0007915 | MONDO:0007915 |
| malignant mesothelioma | 2 | MONDO:0006292 | EFO:1000355 |
| mature T-cell and NK-cell non-Hodgkin lymphoma | 2 | MONDO:0000430 | MONDO:0000430 |
| leukemia | 1 | MONDO:0005059 | EFO:0000565 |
| lymphoid neoplasm | 1 | MONDO:0005157 | EFO:0001642 |
| acute myeloid leukemia | 1 | MONDO:0018874 | EFO:0000222 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 165.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 86 |
| PHASE1 | 27 |
| PHASE1/PHASE2 | 24 |
| PHASE3 | 14 |
| Not specified | 7 |
| PHASE4 | 4 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06831370 | PHASE4 | RECRUITING | A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India |
| NCT01909934 | PHASE4 | COMPLETED | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma |
| NCT01990534 | PHASE4 | COMPLETED | A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma |
| NCT05442554 | PHASE4 | COMPLETED | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma |
| NCT02166463 | PHASE3 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma |
| NCT02661503 | PHASE3 | ACTIVE_NOT_RECRUITING | HD21 for Advanced Stages |
| NCT03907488 | PHASE3 | ACTIVE_NOT_RECRUITING | Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma |
| NCT04404283 | PHASE3 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL |
| NCT04685616 | PHASE3 | RECRUITING | Brentuximab Vedotin in Early Stage Hodgkin Lymphoma |
| NCT05675410 | PHASE3 | RECRUITING | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab |
| NCT06563245 | PHASE2/PHASE3 | RECRUITING | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment |
| NCT07572123 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma |
| NCT01100502 | PHASE3 | COMPLETED | A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) |
| NCT01578499 | PHASE3 | COMPLETED | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
| NCT01712490 | PHASE3 | COMPLETED | A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma |
| NCT01777152 | PHASE3 | COMPLETED | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas |
| NCT02684292 | PHASE3 | COMPLETED | Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) |
| NCT03138499 | PHASE3 | TERMINATED | A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, |
| NCT05711628 | PHASE3 | WITHDRAWN | A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma |
| NCT06186986 | PHASE3 | UNKNOWN | CD30 Imaging in Diffuse Large B-cell Lymphoma |
| NCT01352520 | PHASE2 | ACTIVE_NOT_RECRUITING | SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) |
| NCT01703949 | PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma |
| NCT01896999 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma |
| NCT01920932 | PHASE2 | ACTIVE_NOT_RECRUITING | Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma |
| NCT02734771 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT02758717 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma |
| NCT02979522 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
| NCT03007030 | PHASE2 | RECRUITING | Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery |
| NCT03057795 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma |
| NCT03113500 | PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma |
| NCT03233347 | PHASE2 | ACTIVE_NOT_RECRUITING | Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma |
| NCT03264131 | PHASE2 | ACTIVE_NOT_RECRUITING | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma |
| NCT03356054 | PHASE1/PHASE2 | RECRUITING | Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse |
| NCT03517137 | PHASE2 | ACTIVE_NOT_RECRUITING | Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study |
| NCT03587844 | PHASE2 | RECRUITING | Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients |
| NCT03712202 | PHASE2 | ACTIVE_NOT_RECRUITING | Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma |
| NCT03755804 | PHASE2 | ACTIVE_NOT_RECRUITING | Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 |
| NCT04561206 | PHASE2 | RECRUITING | Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma |
| NCT04587687 | PHASE2 | RECRUITING | Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma |
| NCT04745949 | PHASE2 | RECRUITING | PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).